Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.

Share:
Related MRK
Merck And Premier Join Hands To Prevent Fractures For Osteoporosis Patients
Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment
Expect OraSure To Drop 35% (Or More) Next Week (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Merck & Co. (NYSE: MRK), but lowered its price target from $49.00 to $47.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Merck & Co. closed on Tuesday at $43.34.

Latest Ratings for MRK

DateFirmActionFromTo
Jun 2016JefferiesMaintainsHold
May 2016Credit SuisseMaintainsNeutral
Apr 2016JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!